Evaxion Biotech AS (EVAX)vsRegeneron Pharmaceuticals Inc (REGN)
EVAX
Evaxion Biotech AS
$4.00
+5.82%
HEALTHCARE · Cap: $31.53M
REGN
Regeneron Pharmaceuticals Inc
$732.87
-0.62%
HEALTHCARE · Cap: $80.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 190427% more annual revenue ($14.34B vs $7.53M). REGN leads profitability with a 31.4% profit margin vs -102.4%. REGN earns a higher WallStSmart Score of 58/100 (C).
EVAX
Avoid21
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVAX.
Margin of Safety
-161.4%
Fair Value
$282.06
Current Price
$732.87
$450.81 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -100.2% — below average capital efficiency
Revenue declined 100.0%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : EVAX
The strongest argument for EVAX centers on Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : EVAX
The primary concerns for EVAX are EPS Growth, Market Cap, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
EVAX profiles as a turnaround stock while REGN is a value play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.40 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 21/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evaxion Biotech AS
HEALTHCARE · BIOTECHNOLOGY · USA
Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?